Global Lung Cancer Therapeutics Market- Market Overview

The global lung cancer therapeutics market is expected to reach USD 20.26 billion by 2028, at a CAGR of 10.74% from 2022 to 2028. The increasing incidence of lung cancer in developing and developed regions has led to the rise in demand for lung cancer therapeutics. The rising use of targeted therapies and drugs especially among the geriatric population will drive the growth of the lung cancer therapeutics market. Further, the increasing awareness among the patient population has led to increased use of therapeutics applications. Patient in developing countries is also getting aware of the cancer therapeutics benefits, due to the rising number of awareness programs by public and private organizations.

Lung cancer is characterized by the growth of numerous cells in the lungs. The symptoms include chest pain, cough, breath shortness, weight loss, etc. Lung cancer therapeutics is a part of the early treatment program. Lung cancer therapeutics are conducted on location as well as the size of the tumor. The lung cancer therapeutics also depends on the general health conditions of the patient. The major types of lung cancer include small, non-small cancer, and carcinoid tumor. There are various therapies which include radiation therapy, vaccines, chemotherapy, etc. These therapies are used for different types of lung cancer depending upon the effectiveness.

Lung cancer is even caused by chain-smoking and inhalation of polluted air. There are many lung cancer therapeutics that are approved for application in cancer treatment. The use of lung cancer therapeutics has increased from the previous decade. Lung cancer therapeutics has gone under a transition from traditional drugs and therapies to modern target therapies. Doctors and other healthcare professionals often suggest lung cancer therapeutics to remove the cancer cells.

Request sample:- Global lung cancer therapeutics market

Market Dynamics

Drivers:

• Rising preference for targeted therapies will boost the market growth

The increasing prevalence of lung cancer has resulted in rising in the use of targeted therapies. The target therapies help in eliminating the affected cells without harming the other organs. The rising incidence of lung cancer has increased the demand for targeted therapies. The manufacturers are launching new products for target therapies that can ease out the operation part without any hassle. Healthcare professionals are also adopting target therapies as they are aware of the benefits.

• Increasing research and development

The increasing research and development in the field of lung cancer therapeutics is also promoting the growth of such therapeutics. There are many research studies which are focusing on the development of innovation of lung cancer therapeutics. The implementation of innovative and latest technologies is attractive to various development in lung cancer therapeutics. Lung cancer therapeutics are required for the effective and fast treatment of lung cancer.

Restraints:

• High cost of instruments and kits

The installation cost of lung cancer therapeutics is expensive, and thus it cannot be afforded by many medium and small-scale end-users. There are numerous products involved in the procedure of lung cancer therapeutics, which makes it costlier. Further, the high maintenance cost of the instruments adds up to the total cost.

• The adverse effect of the lung cancer therapeutics

There are potential side-effects of lung cancer therapeutics which restrains the market growth. These adverse effects can cause mild to high difficulties to the patient. Witnessing such adverse effects, many patients hesitate from the lung cancer therapeutics. Chemotherapies can be too painful for the patients as radiation is used in such therapies.

Opportunities:

• The emergence of advanced medical diagnostics

The increasing incidence of lung cancer and other chronic diseases has led to an increase in the use of lung cancer therapeutics in developing as well as developed regions. The healthcare industry is receiving tremendous investment from the government and private players. The development of advanced technology is necessary in order to receive accurate results from therapeutics. The previous systems and therapies had certain technological limitations. The advanced lung cancer therapeutics instruments and systems help in removing the cancer cells effectively.

Challenges

• Imposition of stringent regulations

Lung cancer therapeutics require the passing of stringent regulations in order to be launched in the market. The therapeutics process helps in the removal of cancer cells, which grow abnormally in the lungs. Thus, the approval of lung cancer therapeutics requires the passing of several stages in order to be proved safe for the required applications.

Segmentation Analysis

The global lung cancer therapeutics market has been segmented based on type, therapy, molecule type, end-users, and regions.

By Type

The type segment includes small cell lung cancer, non-small cell lung cancer, and lung carcinoid cancer. The non-small lung cancer segment led the lung cancer therapeutics market with a market share of around 46.02% in 2021. The prevalence of non-small lung cancer is more prevalent as compared to the other types of lung cancer. The cancer research studies have concluded that most of the patients suffer from non-small lung cancer. Thus, the diagnosis of non-small lung cancer is in high demand, especially in UK and US.

By Therapy

The therapy segment includes immunotherapy, targeted therapy, radiotherapy, and chemotherapy. The targeted therapy segment further includes Tarceva, Gilotrif, Iressa, Avastin, and others. The radiotherapy segment further includes internal radiotherapy, external beam radiotherapy, and systematic radiotherapy. The chemotherapy segment further includes Navelbine, Alimta, Gemzar, Paraplatin, Taxotere, and others. The targeted therapy segment led the lung cancer therapeutics market with a market share of around 48.39% in 2021. Targeted therapies are the most effective in the case of lung cancer. Target therapies directly affect the abnormal cell growth and help in removing those without affecting any other body part. Healthcare professionals and patients both are inclined towards the use of lung cancer therapeutics.

By Molecule Type

The molecule type segment includes biologics and small molecules. The small molecule segment led the lung cancer therapeutics market with a market share of around 66.78% in 2021. Small molecules are used widely in the lung cancer therapeutics market. Small molecules help in target therapies for use in cancer indication. Small molecules can easily enter the affected area which increases its efficacy.

By End-users

The end-user segment includes hospitals, diagnostics centers, specialty clinics, and others. The hospital segment led the lung cancer therapeutics market with a market share of around 47.19% in 2021. Hospitals generally provide a high amount of investment for the installation of the instruments and systems used in lung cancer therapeutics. The patients diagnosed with any type of lung cancer must have to visit the hospital facilities for the treatment of the same. Thus, the hospitals keep themselves well equipped with all the latest therapeutics systems.

By Regional Analysis

The regions analyzed for the lung cancer therapeutics market include North America, Europe, South America, Asia Pacific, and the Middle East, and Africa. North America region dominated the automated and closed-cell therapy processing market and held the 39.17% share of the market revenue in 2021.

• The presence of an established healthcare system and increasing investments by the public and private players is one of the primary reasons for the development of lung cancer therapeutics. The manufacturers present in the region, are investing hugely in lung cancer therapeutics and the development of advanced technology systems and instruments. There is a larger number of geriatric populations which suffer from lung cancer. The region is investing in advanced high imaging instruments propelling new growth opportunities for the market.
• The Asia-Pacific region is likely to register the highest growth during the Projection period due to the rising demand for lung cancer therapeutics in the geriatric population. Moreover, India and China are some of the key countries for the lung cancer therapeutics market in the Asia-Pacific region. Further, the rising healthcare spending is fueling up the market growth.

Key Industry Players Analysis

To increase their market position in the global lung cancer therapeutics business, top companies are focusing on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, and partnerships, joint ventures, etc.

• Astellas
• Novartis AG
• Sanofi
• Pfizer Inc.
• AstraZeneca
• Merck Sharp and Dohme Corporation
• Millennium Pharmaceuticals Inc.
• Bristol Myers Squibb
• Celgene Corporation
• Eli Lilly and Company
• Genentech
• Boehringer Ingelheim Pharmaceuticals Inc.
• Agennix AG
• GlaxoSmithKline Plc
• Daiichi Sankyo

Latest Development

• March 2019- A leading player, Adorx Therapeutics Ltd., had announced that it had signed a strategic partnership along with Johnson and Johnson LLC. This partnership had the objective of development of the lung cancer therapeutics. Johnson and Johnson LLC had initiated lung cancer research and development, due to which many companies are willing to form a strategic alliance with them.
• September 2019- AstraZeneca had received authorization approval from the organization, National Medical Products Administration, for Tagrisso. Tagrisso is an EGFR, kinase tyrosine inhibitor. The drug is used for patients who are suffering from EGFR mutated and non-small cells.
• August 2018- F. Hoffmann La Roche had received US FDA approval, for its Cobas EGFR Mutation Test v2. This specific test is a liquid biopsy test that is generally used in combination with the Irresa, which is another EGFR inhibitor for the treatment of non-small lung cancer. This test is considered to be the most effective and useful for NSCLC therapies.

Scope of the Report

Global Lung Cancer Therapeutics Market by Type:

• Small Cell Lung Cancer
• Non-small Cell Lung Cancer
• Lung Carcinoid Cancer

Global Lung Cancer Therapeutics Market by Therapy:

• Immunotherapy
• Targeted Therapy
  • Tarceva
  • Gilotrif
  • Iressa
  • Avastin
  • Others
• Radiotherapy
  • Internal Radiotherapy
  • External Beam Radiotherapy
  • Systematic Radiotherapy
• Chemotherapy
  • Navelbine
  • Alimta
  • Gemzar
  • Paraplatin
  • Taxotere
  • Others

Global Lung Cancer Therapeutics Market by Molecule Type:

• Biologics
• Small Molecules

Global Lung Cancer Therapeutics Market by End-users:

• Hospitals
• Diagnostics Centers
• Specialty Clinics
• Others

Global Lung Cancer Therapeutics Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Korea
  • Southeast Asia
• South America
  • Brazil
  • Peru
• Middle East and Africa
  • UAE
  • South Africa
  • Saudi Arabia

Political- The healthcare industry is receiving tremendous investment from the government and private players. The development of advanced technology is necessary in order to receive accurate results from therapeutics. The previous systems and therapies had certain technological limitations. The advanced lung cancer therapeutics instruments and systems help in removing the cancer cells effectively.

Economic- The installation cost of lung cancer therapeutics is expensive, and thus it cannot be afforded by many medium and small-scale end-users. There are numerous products involved in the procedure of lung cancer therapeutics, which makes it costlier. Further, the high maintenance cost of the instruments adds up to the total cost. Hospitals generally provide a high amount of investment for the installation of the instruments and systems used in lung cancer therapeutics. The patients diagnosed with any type of lung cancer must have to visit the hospital facilities for the treatment of the same. Thus, the hospitals keep themselves well equipped with all the latest therapeutics systems.

Social- The presence of an established healthcare system and increasing investments by the public and private players is one of the primary reasons for the development of lung cancer therapeutics. The manufacturers present in the region, are investing hugely in lung cancer therapeutics and the development of advanced technology systems and instruments. There is a larger number of geriatric populations which suffer from lung cancer. The region is investing in advanced high imaging instruments propelling new growth opportunities for the market.

Technological- The healthcare industry is receiving tremendous investment from the government and private players. The development of advanced technology is necessary in order to receive accurate results from therapeutics. The previous systems and therapies had certain technological limitations. The advanced lung cancer therapeutics instruments and systems help in removing the cancer cells effectively.

Environmental- The main reason for lung cancer is smoking along with pollution. So, in order to cope up with the pollution government is taking several steps such as implementing new regulations and policies to fight pollution.

Legal- A leading player, Adorx Therapeutics Ltd., had announced that it had signed a strategic partnership along with Johnson and Johnson LLC. This partnership had the objective of development of the lung cancer therapeutics. Johnson and Johnson LLC had initiated lung cancer research and development, due to which many companies are willing to form a strategic alliance with them.

1. Introduction
   • Objective Of The Study
   • Overview Of Lung Cancer Therapeutics Market
   • Markets Covered
   • Geographic Scope
   • Years Considered For The Study
   • Currency And Pricing
2. Executive Summary
3. Premium Insights
   • Market Attractiveness Analysis
     • Market Attractiveness Analysis By Type
     • Market Attractiveness Analysis By Therapy
     • Market Attractiveness Analysis By Molecule Type
     • Market Attractiveness Analysis By End-user
     • Market Attractiveness Analysis By Region
   • Industry SWOT
   • Industry Trends
   • Porter’s Five Forces Analysis
   • Country Level Analysis
   • Factors Considered For The Study
   • Pointers Covered At Macro Level
   • Pointers Covered At Micro Level
   • Year On Year Growth Rate
   • Technology Road Map
4. Market Overview and Key Dynamics
   • Drivers
   • Restraints
   • Opportunities
   • Challenges
5. Global Lung Cancer Therapeutics Market Analysis and Projection, By Type
   • Segment Overview
   • Small Cell Lung Cancer
   • Non-small Cell Lung Cancer
   • Lung Carcinoid Cancer
6. Global Lung Cancer Therapeutics Market Analysis and Projection, By Therapy
   • Segment Overview
   • Immunotherapy
   • Targeted Therapy
     • Tarceva
     • Gilotrif
     • Iressa
     • Avastin
     • Others
   • Radiotherapy
     • Internal Radiotherapy
     • External Beam Radiotherapy
     • Systematic Radiotherapy
   • Chemotherapy
     • Navelbine
     • Alimta
     • Gemzar
     • Paraplatin
     • Taxotere
     • Others

7. Global Lung Cancer Therapeutics Market Analysis and Projection, By Molecule Type
   • Segment Overview
   • Biologics
   • Small Molecules
8. Global Lung Cancer Therapeutics Market Analysis and Projection, By End-user
   • Segment Overview
   • Hospitals
   • Diagnostics Centers
   • Specialty Clinics
   • Others
9. Global Lung Cancer Therapeutics Market Analysis and Projection, By Regional Analysis
   • North America
     • USA
     • Canada
     • Mexico
   • Europe
     • Germany
     • France
     • UK
     • Italy
     • Spain
   • Asia-Pacific
     • Japan
     • China
     • India
   • South America
     • Brazil
   • Middle East and Africa
     • UAE
     • South Africa

10. Global Lung Cancer Therapeutics Market-Competitive Landscape
    • Overview
    • Market Share of Key Players in Global Lung Cancer Therapeutics Market
      • Global Company Market Share
      • North America Company Market Share
      • Europe Company Market Share
      • APAC Company Market Share
    • Competitive Situations and Trends
      • Product Launches and Developments
      • Partnerships, Collaborations and Agreements
      • Mergers & Acquisitions
      • Expansions

11. Company Profiles
    • Astellas
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Novartis AG
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Sanofi
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Pfizer Inc.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • AstraZeneca
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Merck Sharp and Dohme Corporation
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Millennium Pharmaceuticals Inc.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Bristol Myers Squibb
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Celgene Corporation
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Eli Lilly and Company
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Genentech
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Boehringer Ingelheim Pharmaceuticals Inc.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Agennix AG, GlaxoSmithKline Plc, Daiichi Sankyo
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • GlaxoSmithKline Plc
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Daiichi Sankyo
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis

List of Table

1. Global Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
2. Global Small Cell Lung Cancer, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
3. Global Non-small Cell Lung Cancer, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
4. Global Lung Carcinoid Cancer, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
5. Global Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
6. Global Immunotherapy, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
7. Global Targeted Therapy, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
8. Global Radiotherapy, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
9. Global Chemotherapy, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
10. Global Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
11. Global Biologics, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
12. Global Small Molecules, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
13. Global Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
14. Global Hospitals, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
15. Global Diagnostics Centers, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
16. Global Specialty Clinics, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
17. Global Others, Lung Cancer Therapeutics Market, By Region, 2021-2028 (USD Billion)
18. North America Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
19. North America Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
20. North America Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
21. North America Lung Cancer Therapeutics Market, By End-user 2021-2028 (USD Billion)
22. US Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
23. US Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
24. US Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
25. US Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
26. Canada Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
27. Canada Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
28. Canada Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
29. Canada Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
30. Mexico Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
31. Mexico Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
32. Mexico Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
33. Mexico Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
34. Europe Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
35. Europe Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
36. Europe Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
37. Europe Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
38. Germany Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
39. Germany Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
40. Germany Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
41. Germany Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
42. France Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
43. France Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
44. France Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
45. France Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
46. UK Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
47. UK Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
48. UK Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
49. UK Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
50. Italy Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
51. Italy Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
52. Italy Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
53. Italy Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
54. Spain Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
55. Spain Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
56. Spain Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
57. Spain Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
58. Asia Pacific Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
59. Asia Pacific Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
60. Asia Pacific Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
61. Asia Pacific Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
62. Japan Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
63. Japan Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
64. Japan Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
65. Japan Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
66. China Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
67. China Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
68. China Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
69. China Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
70. India Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
71. India Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
72. India Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
73. India Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
74. South America Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
75. South America Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
76. South America Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
77. South America Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
78. Brazil Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
79. Brazil Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
80. Brazil Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
81. Brazil Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
82. Middle East and Africa Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
83. Middle East and Africa Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
84. Middle East and Africa Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
85. Middle East and Africa Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
86. UAE Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
87. UAE Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
88. UAE Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
89. UAE Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)
90. South Africa Lung Cancer Therapeutics Market, By Type, 2021-2028 (USD Billion)
91. South Africa Lung Cancer Therapeutics Market, By Therapy, 2021-2028 (USD Billion)
92. South Africa Lung Cancer Therapeutics Market, By Molecule Type, 2021-2028 (USD Billion)
93. South Africa Lung Cancer Therapeutics Market, By End-user, 2021-2028 (USD Billion)

List of Figures

1. Global Lung Cancer Therapeutics Market Segmentation
2. Global Lung Cancer Therapeutics Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Lung Cancer Therapeutics Market Attractiveness Analysis By Type
9. Global Lung Cancer Therapeutics Market Attractiveness Analysis By Therapy
10. Global Lung Cancer Therapeutics Market Attractiveness Analysis By Molecule Type
11. Global Lung Cancer Therapeutics Market Attractiveness Analysis By End-user
12. Global Lung Cancer Therapeutics Market Attractiveness Analysis By Region
13. Global Lung Cancer Therapeutics Market: Dynamics
14. Global Lung Cancer Therapeutics Market Share By Type (2021 & 2028)
15. Global Lung Cancer Therapeutics Market Share By Therapy (2021 & 2028)
16. Global Lung Cancer Therapeutics Market Share By Molecule Type (2021 & 2028)
17. Global Lung Cancer Therapeutics Market Share By End-user (2021 & 2028)
18. Global Lung Cancer Therapeutics Market Share By Regions (2021 & 2028)
19. Global Lung Cancer Therapeutics Market Share By Company (2021)